Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07537413 · ClinicalTrials.gov registry record · Phase 4
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Not yet
- Registry status
- Phase 4
- Development phase
- 430
- Enrollment target
NCT07537413 is a Phase 4 study that has not yet begun recruiting, run by University of Maryland, Baltimore. The registered enrollment target is 430 participants.
The verdict
NCT07537413, a Phase 4 study, has not yet begun recruiting, sponsored by University of Maryland, Baltimore.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 430 participants
- Enrollment target
Study Summary
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.\<p\> Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
Interventions
- DRUG Ceftriaxone 1 gram daily
- DRUG Ceftriaxone 2 grams daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2028-02-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07537413
The ClinicalTrials.gov registry entry for NCT07537413 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 430 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ceftriaxone 1 gram daily is the first listed.
NCT07537413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07537413 about?
NCT07537413 is a clinical study titled "Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia". Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.\<p\> Hypothesis: Among hospitalized patients outside of the...
What is the current status of trial NCT07537413?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 430 participants. The study started on 2026-09-01. Estimated completion is 2028-02-28.
What interventions are being tested in trial NCT07537413?
The interventions under investigation include: Ceftriaxone 1 gram daily (DRUG), Ceftriaxone 2 grams daily (DRUG).
Who is sponsoring clinical trial NCT07537413?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.